Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Resources for You

Resources for You

                        For Industry
          For Veterinarians


                        CVM en español
          Animal Health Literacy Home
          Animal & Veterinary
          Resources for You
          Letter to Industry: Phase-In of Inspectional Activities Related to Compounding of Animal Drugs from Bulk Drug SubstancesResources for You Letter to Industry: Phase-In of Inspectional Activities Related to Compounding of Animal Drugs from Bulk Drug Substances
  
  	
    Share
    Post
    Linkedin

    Email
    PrintDear Stakeholder,

In response to questions from pharmacy compounding stakeholders, the U.S. Food and Drug Administration is sharing our intentions regarding phasing in inspectional activity in relation to the policy in Guidance for Industry #256, “Compounding Animal Drugs from Bulk Drug Substances.”

FDA intends to shift our resources toward routine inspectional activities in April 2023. We will continue to engage stakeholders to address questions and clarify certain aspects of the guidance as we transition into this new inspectional phase.

FDA anticipates a limited number of inspections at State-licensed pharmacies through September 2023. As we transition into inspections in April 2023, FDA’s initial emphasis will be to gather facts about compounding operations in relation to the policies and priorities in GFI #256 and then discuss them with the inspected pharmacy/facility. Information obtained during animal drug compounding inspections will be evaluated in accordance with FDA’s prior notice policy. For situations that do not present human or animal safety concerns, this policy describes “FDA’s practice to afford individuals and firms an opportunity to voluntarily take appropriate and prompt corrective action prior to the initiation of enforcement action.” (See Regulatory Procedures Manual, 10-2.)

With respect to inspections of federally-registered outsourcing facilities, FDA does not intend to conduct routine inspections relating to the enforcement priorities for animal drugs described in GFI 256 until we provide clarification regarding how the policy in GFI 256 applies to these facilities. However, FDA may choose to conduct non-routine inspections at outsourcing facilities related to animal drugs, for instance, in response to evidence of insanitary conditions or to reports of adverse events or product defects associated with animal drugs compounded by these facilities, that may present particular human or animal safety concerns.

FDA does not intend to inspect veterinary care facilities that do not compound animal drugs from bulk drug substances.

We appreciate the ongoing discussions with all stakeholders and we will continue our outreach throughout this transitional period. Please let us know if you have any questions by reaching out to us via CVMCompounding@fda.hhs.gov.

                                                                                  Content current as of:
      03/10/2023Resources for You

          
                        For Industry
          For Veterinarians


                        CVM en español
          Animal Health Literacy
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop